Bio-Rad Laboratories, Inc.

NYSE:BIO

Medical - Devices

Healthcare
$370.17 -0.23%

-$0.65 today

Market cap
$9.95B
Beta
1.08
P/E (TTM)
45.4
EPS (TTM)
$6.26
52W Low $228.40High $343.12

Volume 0.46M

Average 0.38M

BIO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Bio-Rad Laboratories, Inc.NYSE: BIO

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization outflow shrinks to $0

Q2 FY2026 depreciation & amortization was $0, compared with $40.6M a year earlier. Trailing-twelve-month depreciation & amortization was $127.6M. Over 3 fiscal years it compounded at +6.4% a year.

Context

  • Depreciation & amortization amounted to 6.4% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $31.9M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$165.4M+9.1% YoY
LTMJun 2026
$127.6M-23.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+9.1%——
3-year CAGR+6.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
165.4M USD
Year-over-year change
+9.1%
4-year CAGR
+4.7%

Depreciation & Amortization vs competitors

How BIO compares with its peers on the latest reported figures

  • BIO's LTM Jun 2026 depreciation & amortization of $127.6M is the 5th largest of the 11 companies compared; the peer median is $97.03M.
  • Its year-over-year change of -23.5% is the 9th highest of 11, against a peer median of -7.3%.
  • Depreciation & amortization amounts to 4.9% of revenue for BIO, versus a peer median of 10.1%.
BIO Competitors Peer median
Depreciation & Amortization for BIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$3.11B +11.2%-6.3%6.6%
DHRDanaher CorporationLTM Sep 2026$1.91B -21.1%+4.7%7.5%
RVTYRevvity, Inc.LTM Jul 2026$412.24M -0.2%-1.7%14.2%
BRKRBruker CorporationLTM Jun 2026$230.1M +9.4%+35.4%6.6%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M -23.5%+6.4%4.9%
RGENRepligen CorporationLTM Jun 2026$97.31M -7.0%+19.4%12.4%
TECHBio-Techne CorporationLTM Sep 2026$96.75M -8.8%-3.2%7.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$56.96M -3.2%+16.6%27.3%
AZTAAzenta, Inc.LTM Sep 2026$56.52M -7.7%-12.9%9.1%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$17.69M -95.7%+181.5%11.1%
LABStandard BioTools Inc.LTM Mar 2026$10.99M -30.6%-51.5%12.7%
Peer median (excluding BIO) $97.03M-7.3%+1.5%10.1%

Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income4.25B(3.63B)(637.3M)(1.84B)759.9M
Depreciation & Amortization137.6M137.3M145.9M151.6M165.4M
Deferred Income Tax00000
Stock-Based Compensation51.2M60.9M61.3M62.3M58M
Change in Working Capital1.14B(1.61B)(432.8M)(620.8M)272.4M
Accounts Receivables(20.4M)(87.4M)11.4M16.2M19.6M
Inventory46.1M(158.8M)(46.3M)8.5M68.9M
Accounts Payables69.9M(94.2M)(51.8M)(40.9M)(100K)
Other Working Capital1.05B(1.27B)(346.1M)(604.6M)184M
Other Non-Cash Items(4.92B)5.23B1.24B2.71B(723.5M)
Operating Cash Flow669.46M194.45M374.94M455.2M532.2M
Capital Expenditures(133.75M)(114.16M)(156.68M)(189M)(157.6M)
Acquisitions (Net)(125.52M)(99.39M)2.5M0(218.4M)
Purchases of Investments(851.63M)(2.06B)(689.04M)(1.28B)(669.3M)
Sales of Investments766.9M1.07B863.22M1.31B62M
Other Investing Activities(453.39M)(1.21M)211K(23.3M)793.6M
Investing Cash Flow(797.38M)(1.21B)20.21M(160.2M)(189.7M)
Debt Repayment(3.02M)1.19B(467K)(400K)(500K)
Common Stock Issued000015.8M
Common Stock Repurchased(50M)(215.68M)(428.73M)(203.6M)(295.5M)
Dividends Paid00000
Other Financing Activities(2.41M)3.55M3.55M(14.8M)(3M)
Financing Cash Flow(55.43M)973.58M(425.65M)(218.8M)(283.2M)
Effect of Forex Changes(12.64M)2.98M321K9.2M(19M)
Net Change in Cash(195.98M)(36.59M)(30.18M)85.4M40.3M
Free Cash Flow535.72M80.29M218.26M266.2M374.6M

Bio-Rad Laboratories, Inc.

NYSE:BIO

Intrinsic Alpha fair value

Locked

Current Price

$370.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.